`Share of Prescriptions
`
`EXHIBIT 2044
`
`Re)
`
`100%
`
`90%
`
`80%
`
`70%
`
`60%
`
`50%
`
`40%
`
`30%
`
`20%
`
`10%
`
`0%
`
`cERy/
`
`10.5%
`
`a ae
`
`15.4%
`
`aR 12.7%
`
`2006
`
`2007
`
`2008
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`2015
`
`2016
`
`2017
`
`BTRAVATAN Z® BS TRAVATAN® @LUMIGAN® @ZIOPTAN™ @XALATAN® ms RESCULA® SiLatanoprost @Travoprost @Bimatoprost
`Source:
`/QVIA
`Note: TRAVATAN Z® was launched in October 2006. Data for 2017 are available through October. The values for November and December 2017 are projected
`on the basis of the average yearly proportion of the number of prescriptions in November and December for the previous three years. For bimatoprost, the values
`for November and December 2017 are projected on the basis of the proportion of the number of prescriptions in November and December for the previous year.
`
`CONFIDENTIAL-PROTECTIVE ORDER MATERIAL
`
`ALCON2044
`Argentum Pharm. LLC v. Alcon Research, Ltd.
`Case IPR2017-01053
`
`